Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Biotechnol Appl Biochem ; 64(5): 735-744, 2017 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-27506960

RESUMO

Limit of detection (LOD), limit of quantification, and the dynamic range of detection of hepatitis B surface antigen antibody (anti-HBs) using a surface plasmon resonance (SPR) chip-based approach with Pichia pastoris-derived recombinant hepatitis B surface antigen (HBsAg) as recognition element were established through the scouting for optimal conditions for the improvement of immobilization efficiency and in the use of optimal regeneration buffer. Recombinant HBsAg was immobilized onto the sensor surface of a CM5 chip at a concentration of 150 mg/L in sodium acetate buffer at pH 4 with added 0.6% Triton X-100. A regeneration solution of 20 mM HCl was optimally found to effectively unbind analytes from the ligand, thus allowing for multiple screening cycles. A dynamic range of detection of ∼0.00098-0.25 mg/L was obtained, and a sevenfold higher LOD, as well as a twofold increase in coefficient of variance of the replicated results, was shown as compared with enzyme-linked immunosorbent assay (ELISA). Evaluation of the assay for specificity showed no cross-reactivity with other antibodies tested. The ability of SPR chip-based assay and ELISA to detect anti-HBs in human serum was comparable, indicating that the SPR chip-based assay with its multiple screening capacity has greater advantage over ELISA.


Assuntos
Anticorpos Anti-Hepatite B/sangue , Anticorpos Anti-Hepatite B/metabolismo , Antígenos de Superfície da Hepatite B/metabolismo , Proteínas Imobilizadas/metabolismo , Ressonância de Plasmônio de Superfície/métodos , Ensaio de Imunoadsorção Enzimática , Antígenos de Superfície da Hepatite B/química , Humanos , Proteínas Imobilizadas/química , Limite de Detecção , Modelos Lineares , Técnicas Analíticas Microfluídicas , Pichia , Proteínas Recombinantes/química , Proteínas Recombinantes/metabolismo , Reprodutibilidade dos Testes
2.
Genome Announc ; 3(3)2015 Jun 04.
Artigo em Inglês | MEDLINE | ID: mdl-26044413

RESUMO

The complete genome sequence of the ALL-03 strain of rat cytomegalovirus (RCMV) has been determined. The RCMV genome has a length of 197,958 bp and is arranged as a single unique sequence flanked by 504-bp terminal direct repeats. This strain is closely related to the English strain of RCMV in terms of genetic arrangement but differs slightly in size.

3.
Int J Nanomedicine ; 10: 1649-66, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-25767386

RESUMO

Cancer nanotherapy is progressing rapidly with the introduction of many innovative drug delivery systems to replace conventional therapy. Although the antitumor activity of zerumbone (ZER) has been reported, there has been no information available on the effect of ZER-loaded nanostructured lipid carrier (NLC) (ZER-NLC) on murine leukemia cells. In this study, the in vitro and in vivo effects of ZER-NLC on murine leukemia induced with WEHI-3B cells were investigated. The results from 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide, Hoechst 33342, Annexin V, cell cycle, and caspase activity assays showed that the growth of leukemia cells in vitro was inhibited by ZER-NLC. In addition, outcomes of histopathology, transmission electron microscopy, and Tdt-mediated dUTP nick-end labeling analyses revealed that the number of leukemia cells in the spleen of BALB/c leukemia mice significantly decreased after 4 weeks of oral treatment with various doses of ZER-NLC. Western blotting and reverse-transcription quantitative polymerase chain reaction assays confirmed the antileukemia effects of ZER-NLC. In conclusion, ZER-NLC was shown to induce a mitochondrial-dependent apoptotic pathway in murine leukemia. Loading of ZER in NLC did not compromise the anticancer effect of the compound, suggesting ZER-NLC as a promising and effective delivery system for treatment of cancers.


Assuntos
Antineoplásicos , Leucemia/tratamento farmacológico , Nanoestruturas/química , Sesquiterpenos , Animais , Antineoplásicos/química , Antineoplásicos/farmacologia , Antineoplásicos/uso terapêutico , Apoptose/efeitos dos fármacos , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Portadores de Fármacos/química , Lipídeos/química , Camundongos , Sesquiterpenos/química , Sesquiterpenos/farmacologia , Sesquiterpenos/uso terapêutico
4.
Int J Nanomedicine ; 9: 527-38, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24549090

RESUMO

This investigation evaluated the antileukemia properties of a zerumbone (ZER)-loaded nanostructured lipid carrier (NLC) prepared by hot high-pressure homogenization techniques in an acute human lymphoblastic leukemia (Jurkat) cell line in vitro. The apoptogenic effect of the ZER-NLC on Jurkat cells was determined by fluorescent and electron microscopy, Annexin V-fluorescein isothiocyanate, Tdt-mediated dUTP nick-end labeling assay, cell cycle analysis, and caspase activity. An MTT (3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide) assay showed that ZER-NLC did not have adverse effects on normal human peripheral blood mononuclear cells. ZER-NLC arrested the Jurkat cells at G2/M phase with inactivation of cyclin B1 protein. The study also showed that the antiproliferative effect of ZER-NLC on Jurkat cells is through the intrinsic apoptotic pathway via activation of caspase-3 and caspase-9, release of cytochrome c from the mitochondria into the cytosol, and subsequent cleavage of poly (adenosine diphosphate-ribose) polymerase (PARP). These findings show that the ZER-NLC is a potentially useful treatment for acute lymphoblastic leukemia in humans.


Assuntos
Antineoplásicos/administração & dosagem , Leucemia de Células T/tratamento farmacológico , Nanoestruturas/administração & dosagem , Nanoestruturas/química , Sesquiterpenos/administração & dosagem , Apoptose/efeitos dos fármacos , Caspases/metabolismo , Fragmentação do DNA/efeitos dos fármacos , Portadores de Fármacos/química , Sistemas de Liberação de Medicamentos , Pontos de Checagem da Fase G2 do Ciclo Celular/efeitos dos fármacos , Humanos , Células Jurkat , Leucemia de Células T/metabolismo , Leucemia de Células T/patologia , Lipídeos/química , Mitocôndrias/efeitos dos fármacos , Mitocôndrias/metabolismo , Modelos Biológicos , Nanomedicina , Nanoestruturas/ultraestrutura
5.
Int J Nanomedicine ; 8: 2769-81, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23946649

RESUMO

Zerumbone, a natural dietary lipophilic compound with low water solubility (1.296 mg/L at 25°C) was used in this investigation. The zerumbone was loaded into nanostructured lipid carriers using a hot, high-pressure homogenization technique. The physicochemical properties of the zerumbone-loaded nanostructured lipid carriers (ZER-NLC) were determined. The ZER-NLC particles had an average size of 52.68 ± 0.1 nm and a polydispersity index of 0.29 ± 0.004 µm. Transmission electron microscopy showed that the particles were spherical in shape. The zeta potential of the ZER-NLC was -25.03 ± 1.24 mV, entrapment efficiency was 99.03%, and drug loading was 7.92%. In vitro drug release of zerumbone from ZER-NLC was 46.7%, and for a pure zerumbone dispersion was 90.5% over 48 hours, following a zero equation. Using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay in human T-cell acute lymphoblastic leukemia (Jurkat) cells, the half maximal inhibitory concentration (IC50) of ZER-NLC was 5.64 ± 0.38 µg/mL, and for free zerumbone was 5.39 ± 0.43 µg/mL after 72 hours of treatment. This study strongly suggests that ZER-NLC have potential as a sustained-release drug carrier system for the treatment of leukemia.


Assuntos
Antineoplásicos/química , Portadores de Fármacos/química , Lipídeos/química , Nanopartículas/química , Sesquiterpenos/química , Análise de Variância , Antineoplásicos/farmacocinética , Antineoplásicos/farmacologia , Sobrevivência Celular/efeitos dos fármacos , Cristalização , Portadores de Fármacos/farmacocinética , Portadores de Fármacos/farmacologia , Estabilidade de Medicamentos , Humanos , Concentração de Íons de Hidrogênio , Células Jurkat , Leucemia , Lipídeos/farmacocinética , Lipídeos/farmacologia , Testes de Sensibilidade Microbiana , Tamanho da Partícula , Sesquiterpenos/farmacocinética , Sesquiterpenos/farmacologia , Difração de Raios X
6.
In Vitro Cell Dev Biol Anim ; 49(3): 238-44, 2013 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-23435855

RESUMO

Endothelial cells have been implicated as key cells in promoting the pathogenesis and spread of cytomegalovirus (CMV) infection. This study describes the isolation and culture of rat brain endothelial cells (RBEC) and further evaluates the infectious potential of a Malaysian rat CMV (RCMV ALL-03) in these cultured cells. Brain tissues were mechanically fragmented, exposed to enzymatic digestion, purified by gradient density centrifugation, and cultured in vitro. Morphological characteristics and expression of von Willebrand factor (factor VIII-related antigen) verified the cells were of endothelial origin. RBEC were found to be permissive to the virus by cytopathic effects with detectable plaques formed within 7 d of infection. This was confirmed by electron microscopy examination which proved the existence of the viral particles in the infected cells. The susceptibility of the virus to these target cells under the experimental conditions described in this report provides a platform for developing a cell-culture-based experimental model for studies of RCMV pathogenesis and allows stimulation of further studies on host cell responses imposed by congenital viral infections.


Assuntos
Células Endoteliais/metabolismo , Muromegalovirus/isolamento & purificação , Animais , Encéfalo/metabolismo , Encéfalo/patologia , Encéfalo/virologia , Infecções por Citomegalovirus/metabolismo , Infecções por Citomegalovirus/patologia , Infecções por Citomegalovirus/virologia , Efeito Citopatogênico Viral , Suscetibilidade a Doenças , Células Endoteliais/patologia , Células Endoteliais/virologia , Endotélio Vascular/metabolismo , Endotélio Vascular/patologia , Endotélio Vascular/virologia , Fibroblastos/citologia , Fibroblastos/metabolismo , Fibroblastos/virologia , Muromegalovirus/metabolismo , Muromegalovirus/patogenicidade , Ratos , Fator de von Willebrand/metabolismo
7.
Vet Med Int ; 20102010 Jul 28.
Artigo em Inglês | MEDLINE | ID: mdl-20798771

RESUMO

Feline coronaviruses (FCoVs) are found throughout the world. Infection with FCoV can result in a diverse range of signs from clinically inapparent infections to a highly fatal disease called feline infectious peritonitis (FIP). FIP is one of the most serious viral diseases of cats. While there is neither an effective vaccine, nor a curative treatment for FIP, a diagnostic protocol for FCoV would greatly assist in the management and control of the virus. Clinical findings in FIP are non-specific and not helpful in making a differential diagnosis. Haematological and biochemical abnormalities in FIP cases are also non-specific. The currently available serological tests have low specificity and sensitivity for detection of active infection and cross-react with FCoV strains of low pathogenicity, the feline enteric coronaviruses (FECV). Reverse transcriptase polymerase chain reaction (RT-PCR) has been used to detect FCoV and is rapid and sensitive, but results must be interpreted in the context of clinical findings. At present, a definitive diagnosis of FIP can be established only by histopathological examination of biopsies. This paper describes and compares diagnostic methods for FCoVs and includes a brief account of the virus biology, epidemiology, and pathogenesis.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA